News
Novo Nordisk stock slumped early Monday as the drugmaker was facing a potential hit to revenue from several different ...
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results